22 related articles for article (PubMed ID: 38554542)
1. Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer.
Lee S; Kim JY; Lee SJ; Hwang CS; Lee HJ; Kim KB; Lee JH; Shin DH; Choi KU; Lee CH; Huh GY; Kim A
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792920
[No Abstract] [Full Text] [Related]
2. Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A systematic review and meta-analysis.
Han W; Zhang DD; Zhang YW; Shi LZ; Wang HN
Eur J Cancer; 2024 May; ():114126. PubMed ID: 38797636
[No Abstract] [Full Text] [Related]
3. Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Lederer B; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kümmel S; Loibl S; Paepke S; Untch M; von Minckwitz G; Schneeweiss A
Eur J Cancer; 2016 Jan; 53():65-74. PubMed ID: 26693900
[TBL] [Abstract][Full Text] [Related]
4. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
5. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
[TBL] [Abstract][Full Text] [Related]
6. Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Ilie SM; Briot N; Constantin G; Roussot N; Ilie A; Bergeron A; Arnould L; Beltjens F; Desmoulin I; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Amet A; Coutant C; Coudert B; Bertaut A; Ladoire S
Breast Cancer; 2023 Nov; 30(6):997-1007. PubMed ID: 37561255
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
8. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
9. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.
Moldoveanu D; Hoskin TL; Day CN; Schulze AK; Goetz MP; Boughey JC
Breast Cancer Res Treat; 2024 Feb; 203(3):419-428. PubMed ID: 37878154
[TBL] [Abstract][Full Text] [Related]
10. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B
Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375
[TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
